Morgan Stanley Bio Restorative Therapies, Inc. Transaction History

Morgan Stanley

$1.36 Trillion
Q1 2025

A detailed history of Morgan Stanley transactions in Bio Restorative Therapies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 38,000 shares of BRTX stock, worth $65,360. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,000

Previous 27,500 38.18%

Holding current value

$65,360

Previous $38,000 76.32%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.49 - $2.49 $15,645 - $26,145	10,500 Added 38.18%	38,000 $67,000
Q4 2024 Feb 14, 2025	BUY	$1.33 - $1.73 $13,300 - $17,300	10,000 Added 57.14%	27,500 $38,000
Q3 2024 May 14, 2025	BUY	$1.32 - $1.98 $3,300 - $4,950	2,500 Added 16.67%	17,500 $30,000
Q3 2024 Nov 14, 2024	BUY	$1.32 - $1.98 $3,300 - $4,950	2,500 Added 16.67%	17,500 $30,000
Q2 2024 May 14, 2025	SELL	$1.15 - $2.22 $14,374 - $27,750	-12,500 Reduced 45.45%	15,000 $30,000
Q2 2024 Oct 17, 2024	BUY	$1.15 - $2.22 $5,750 - $11,100	5,000 Added 50.0%	15,000 $30,000
Q2 2024 Aug 14, 2024	BUY	$1.15 - $2.22 $5,750 - $11,100	5,000 Added 50.0%	15,000 $30,000
Q1 2024 Oct 17, 2024	SELL	$1.28 - $3.45 $6,400 - $17,250	-5,000 Reduced 33.33%	10,000 $13,000
Q1 2024 Aug 16, 2024	SELL	$1.28 - $3.45 $6,400 - $17,250	-5,000 Reduced 33.33%	10,000 $13,000
Q1 2024 May 15, 2024	BUY	$1.28 - $3.45 $12,800 - $34,500	10,000 New	10,000 $13,000
Q2 2022 Aug 15, 2022	SELL	$2.95 - $5.85 $73 - $146	-25 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$3.3 - $5.69 $82 - $142	25 New	25 $0
Q1 2022 May 13, 2022	BUY	$3.3 - $5.69 $82 - $142	25 New	25 $0

Others Institutions Holding BRTX

# of Institutions

Shares Held

282K

Call Options Held

Put Options Held

View Full List

About BioRestorative Therapies, Inc.

Ticker BRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 3,650,030
Market Cap $6.28M
Description
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtx...

More about BRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account